ArticleRespiratory research2026
Identification and validation of SPP1 as a prognostic biomarker in interstitial lung disease subtypes by single-cell sequencing.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInterstitial lung diseases (ILDs) are a heterogeneous group of disorders with diverse clinical trajectories, highlighting the need for reliable biomarkers for prognostic assessment and risk stratification.
methodsSingle-cell RNA sequencing (scRNA-seq) was performed on explanted lung tissue from 3 patients with idiopathic pulmonary fibrosis (IPF) and 3 control subjects. Secreted phosphoprotein 1 (SPP1) was identified and further validated in serum samples from two ILD cohorts comprising 74 patients with IPF and 92 with idiopathic inflammatory myopathy-associated ILD (IIM-ILD), as well as 56 healthy controls (HCs). Patients with IPF were further classified as acute exacerbation (AE) or stable IPF, and patients with IIM-ILD as rapidly progressive (RP) or stable IIM-ILD. The association between serum SPP1 levels and 1-year all-cause mortality was assessed using Cox proportional hazards models.
resultsscRNA-seq demonstrated that SPP1 expression was markedly upregulated in explanted lungs from IPF patients compared with controls. Serum SPP1 levels were significantly higher in patients with ILD than in HCs (P < 0.001), and were further elevated in AE-IPF (P < 0.001), RP-IIM-ILD (P < 0.001), and anti-melanoma differentiation-associated gene 5-positive IIM-ILD (P = 0.015). The 1-year mortality rates were 35.1% in patients with IPF and 31.5% in those with IIM-ILD. In multivariable Cox analyses, serum SPP1 was an independent predictor of 1-year mortality in the overall ILD cohort (hazard ratio [HR] 1.007, 95% confidence interval [CI] 1.002-1.012, P = 0.005), as well as in the IPF (HR 1.015, 95% CI 1.003-1.027, P = 0.012) and IIM-ILD (HR 1.007, 95% CI 1.001-1.012, P = 0.022) subgroups.
conclusionsSerum SPP1 may serve as a potential biomarker for risk stratification and prognostic assessment in IPF and IIM-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.